The incidence of adrenal insufficiency was 17.0% in combination therapy, 4.7% in anti-PD-1 therapy, 2.2% in anti-PD-L1 therapy, 4.2% in anti-CTLA-4 therapy, and 1.8% in sequential therapy of anti-PD-1 and PD-L1. This evidence concerns the gene PDCD1 and Adrenal insufficiency.